Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SGN-BB228
i
Other names:
SGN-BB228, PRS-346
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Pieris Pharmaceuticals, Seagen
Drug class:
CD137 agonist, Melanotransferrin modulator
Related drugs:
‹
PRS-343 (8)
ABL105 (1)
ALG.APV-527 (1)
HK013 (1)
Opal (1)
TJ-CD4B (1)
PF-05082566 (1)
PRS-343 (8)
ABL105 (1)
ALG.APV-527 (1)
HK013 (1)
Opal (1)
TJ-CD4B (1)
PF-05082566 (1)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MELTF expression
Solid Tumor
MELTF expression
Solid Tumor
SGN-BB228
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
SGN-BB228
Sensitive
:
D
AACR 2023 - 1wk
SGN-BB228
Sensitive: D – Preclinical
AACR 2023 - 1 week
SGN-BB228
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login